NKGEN BIOTECH (NKGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

NKGN NKGEN BIOTECH

Watchlist

0.350
+0.013+3.70%

Close Nov 22 16:00 ET

0.357
+0.007+2.00%

Post 19:50 ET

12.43MMarket Cap-92P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | NKGen Biotech - Co's Inability to Pay Its Payroll Obligations May Result in Employees Terminating Relationship With Co and/or Pursuing Legal Remedies
ReutersOct 30 17:26 ET
Express News | NKGen Biotech Inc - on Oct 24, Co Placed 19 Employees on Furlough, Effective October 27
ReutersOct 30 17:24 ET
Express News | NKGen Biotech Shares Are Trading Lower. The Company Announced the Presentation of Two Posters, on Its First-in-kind, Autologous, Non-genetically Modified NK Cell Product, Troculeucel, in Alzheimer's Disease
BenzingaOct 29 10:59 ET
Express News | NKGen Biotech Presents Phase 1/2a Data On Troculeucel In Alzheimer's Disease At CTAD Conference, Showing Biomarker Reductions And Cognitive Improvement; Highest Dose Demonstrates Safety With Potential To Delay Dementia
BenzingaOct 29 08:07 ET
Express News | NKGen Biotech Announces Poster Presentations at the 17TH Annual Clinical Trials on Alzheimer’s Disease (Ctad) Conference
ReutersOct 8 08:05 ET
12 Health Care Stocks Moving In Friday's After-Market Session
BenzingaOct 4 16:31 ET

Comments

Jaguar8

Oct 29 07:16

NEWS

$NKGEN BIOTECH (NKGN.US)$
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
NKGen Biotech presented Phase 1/2a trial data for troculeucel in Alzheimer's Disease at the CTAD Conference. The Phase 1 trial showed that troculeucel reduces several biomarkers detectable up to 10 years before dementia symptoms. In the Phase 1/2a trial, using the highest dose of 6 billion cells, all three treated sub...